This blog describes a typical ILD patient journey from the initial diagnosis through its long-term management to end-of-life ...

Findings of a systematic review highlight the need for standardized assessment tools and targeted treatments for chronic ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

Ioannis Sapountzis, head of global therapeutic areas at Boehringer, said that FIBRONEER-IPF is the largest trial in IPF ...

Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five presentations and one poster across its commercial and development portfolio will be presented ...

Patients with vs without keloids had a higher prevalence of interstitial lung disease after controlling for patient specific factors.

Diffuse (interstitial) lung disease includes a wide variety of relatively uncommon conditions presenting with characteristic clusters of clinical features and marked by an immune response.

ECMO or ventilator use was the most significant predictor of mortality in patients undergoing lung transplant for idiopathic ...